Rapid 4th generation POC HIV test identifies acute infection earlier than antibody only tests Inverness Medical announce the new 4th generation rapid HIV diagnostic test – Determine? HIV 1/2 Ag/Ab Combo – capable of detecting HIV infection several days earlier than HIV antibody only tests and is ideal to help diagnose and screen for early HIV infection. The ability of this test to enhance the diagnosis of those with acute HIV infection will provide additional benefits in HIV prevention programs and ultimately contribute to a reduction in the spread of HIV. Inverness Medical will be showcasing the new Determine Combo test at the International AIDS Society Conference 2009 in Capetown, South Africa, 19-22 July on stand #203. Determine HIV-1/2 Ag/Ab Combo enables simultaneous separate detection of HIV p24 antigen (Ag) and antibodies (Ab) for HIV-1 and HIV-2 in human serum, plasma, or whole blood. The p24 antigen is produced during the first few weeks of HIV infection and is detectable 7-9 days earlier than the appearance of HIV antibodies. As a result, the p24 antigen is an ideal marker in aiding early HIV diagnosis. By simultaneously detecting for all known sub types of HIV and HIV-1 p24 antigen, as a CE marked test, Determine HIV-1/2 Ag/Ab Combo increases the ability to detect and diagnose primary HIV infection (2-20 days earlier than HIV antibody only tests, with an average mean of 5 days) and can help healthcare workers across the world diagnose primary infection, prevent mother to child transmission, monitor HIV prevalence and screen blood donations. By understanding their HIV status, individuals are able to gain early access to specific treatment, care and counselling, prevent transmission, and plan for the future. The first test of its kind for acute HIV infection, Determine HIV 1/2 Ag/Ab Combo provides clear visual results during the patient visit in 20 minutes, with excellent sensitivity of 100% and a specificity of 99.23% and 99.66% for HIV antibodies and HIV-1 p24 antigen respectively. The easy to use, robust format of Determine does not require electricity, water, or the use of bulky laboratory equipment and can be performed in point-of-care settings and remote locations in developing countries where laboratory facilities are limited. This gives significant advantages over lab-based EIA and ELISA 4th generation HIV testing.                  

     因弗内斯医疗宣布新的第四代艾滋病毒快速诊断测试-确诊?艾滋病病毒1 / 2抗原/抗体组合-具有比艾滋病病毒抗体检测提前数天并可以理想的帮助诊断和筛查早期艾滋病毒感染的能力.这个检测能够加强急性感染艾滋病毒的诊断并将为预防艾滋病病毒项目提供额外的益处,最终有助于减少艾滋病病毒的蔓延.因弗内斯医疗将会在南非开普敦7月19至22日国际艾滋病协会2009年会展示的新的确诊组合检测. 确诊艾滋病病毒的1 / 2抗原/抗体组合能同时单独检测在人血清,血浆或全血中的艾滋病病毒HIV - 1和HIV – 2的p24抗原（ AG ）和抗体（抗体）. p24抗原产生于艾滋病病毒感染后的前几个星期并比艾滋病病毒抗体提前7-9天检测出.因此, p24抗原是一种帮助艾滋病病毒早期诊断的理想标记. 通过同时检测所有已知亚型的艾滋病病毒和HIV - 1病毒p24抗原,作为主要标记检测,确诊艾滋病病毒的1 / 2抗原/抗体组合增加了检测和诊断初期感染艾滋病毒的能力（比只做艾滋病病毒抗体测试提前2至20天,平均只需5天） ,并可以帮助医务工作者在世界各地诊断初期感染,防止母婴传播,监测艾滋病毒的流行和筛查献血者.通过了解他们的艾滋病病毒状况,每位个体都能够得到早期进行明确具体的治疗、护理和咨询、预防传染,并计划未来. 首次针对急性感染艾滋病病毒的测试表明,确诊艾滋病毒1 / 2抗原/抗体组合在病人就诊的20分钟内提供了清晰的视觉效果,具有出色的灵敏度为100 ％ ,艾滋病病毒抗体和HIV - 1 p24抗原特异性分别为99.23 ％和99.66 ％.易于使用、强大格式的确诊并不需要电,水,或使用笨重的实验室设备,并可以在保健点和发展中国家实验室设施有限的偏远地区进行.这使其相比实验室为基础的第三代双抗原夹心法和第四代艾滋病病毒检测酶联免疫吸附法更具明显优势.

相关阅读
我科学家发现甲亢致病新机理
最重大的卵巢癌致病基因RAD51D发现
解致病变异基因之谜：新脑癌基因的发现